View as an RSS Feed
View Derek Lowe's Articles BY TICKER:
ABBV, ABT, ACOR, AFFY, ALNY, AMGN, ARIA, ARNA, ASTX, AVEO, AZN, BIIB, BMS, BTIM, CEPH, CPRX, DNDN, ELN, ESALY, EXEL, GALE, GE, GNBT, GNVC, GS, GSK, ITMN, JNJ, KVPBQ, LLY, MDVN, MEDX, MNKD, MRK, MTXX, MYGN, NTMD, NVO, NVS, OSIR, OSUKF, PFE, PTCT, RBXLF, RBXZF, RDEA, REGN, RHHBY, RNN, RUK, SEPR, SGP, SNSS, SNY, SQNM, SVNTQ, TKPHF, TRGT, VNDA, VPHM, VSTM, WYE
- The Patent System and the High Price of Cephalon's Arsenic Treatment
- Genzyme's Controversial Buyback was Predictable
The Next Wonder Drug or the Next Big Risk?
on Sep. 10, 2007 • Comment!
- Is the Pzifer-Wyeth Merger Speculation for Real?
- Rumors of Novartis Buyout of Bayer-Schering Surface Again
- Amgen's Alantos Purchase: What's the Use?
- Exubera Proves It: Pfizer's Marketing Can Get It Only So Far
- Pfizer: Run! Anthropologists!
- Genentech: Incomprehension, Out For A Stroll
- GlaxoSmithKline Wins The Latest Round on Avandia
- Roche Holdings: Is Glucokinase Activation Dead as a Target?
- Roche Recalls Contaminated Drug
- GlaxoSmithKline's Weight Loss Drug Alli: Just Another Short Lived Superstar
- Sanofi-aventis' Rimonabant: Will the 'Blue Sky Scenario' Descend to Earth?
- The Bad News is Out on Sanofi-Aventis' Weight Loss Drug
- GlaxoSmithKline Defends Avandia Against Charges of Cardiovascular Risks
- GlaxoSmithKline's Avandia: Trouble or Not?
- Patent Nonsense: Why Drug Development Deserves IP Protection - And Yoga Doesn't
- Why is Brazil Pirating Merck's AIDS Drug?
- Pfizer's New HIV Drug Approval- So What?
- AstraZeneca To Buy MedImmune: Did They Overpay?
- Pfizer: Research Staff Layoffs and Exubera Relaunch
- Cramer's Bad Call On Dendreon: Real World vs. Television